1. Introduction {#s0005}
===============

Cognitive impairment is a prominent and difficult to treat feature of schizophrenia (SZ) and is directly related to functional disability. The lack of progress toward novel and effective interventions is due, at least in part, to the fact that the underlying etiology of cognitive dysfunction in SZ is not known; however, convergent data support a neurodevelopmental model in which genetic factors play a significant role ([@bb0065]).

Genome-wide association studies (GWAS) have reached beyond the candidate gene level in very large samples and have identified several novel risk variants with high statistical confidence. Among the most widely studied of these is a variant in the gene coding for the alpha 1C subunit of the L-type voltage-gated calcium channel (CACNA1C) ([@bb0180]). A single nucleotide polymorphism (SNP; rs1006737) in CACNA1C; initially associated with bipolar disorder (BD) ([@bb0080]; [@bb0180]; [@bb0205]) has also been linked with SZ ([@bb0060]; [@bb0095]; [@bb0100]; [@bb0170]) and recurrent major depression ([@bb0095]). More recently, large-scale GWAS studies ([@bb0060]; [@bb0180]) have reported transdiagnostic associations with multiple SNPs within CACNA1C, highlighting its unique convergence across disorders and underscoring its probably importance for understanding the brain as affected by neuropsychiatric disturbance. Indeed, several subsequent studies have evaluated the effects of CACNA1C variation on neurocognitive capacity in healthy samples as well as in patients with SZ and bipolar disorder (BD); risk carriers evidence impairments in several cognitive domains. CACNA1C rs1006737 has been shown to affect neural networks underlying reward and emotional processing ([@bb0015]; [@bb0245]), verbal fluency ([@bb0135]), verbal memory ([@bb0055]), alerting and orienting aspects of attention ([@bb0225]), and executive functions ([@bb0015]; [@bb0210]); however, not all studies have been positive ([@bb0105]; [@bb0190]). [Table 1](#t0005){ref-type="table"} summarizes the current literature (for recent review see [@bb0155]).Table 1Literature on relationship between CACNA1C and cognition in BD and SZ.Table 1PublicationSubjectsCognitive testsResults: *CACNA1C* & cognitionSNP, rs\#([@bb0055])157 healthy\
557 broad psychosis\
409 SZ/SZASWM (CANTAB)\
In replication studies:\
MATRICS working memory (Cardiff)\
N-back, DS (WAIS), SS (WAIS) (Germany)-Associated with increased errors on CANTAB-Association in same direction within diagnostic groups (broad, narrow, HC), but was nonsignificant in HC-No association for verbal working memory-In replication analyses in two other samples: Cardiff (no association for working memory, but was associated with verbal memory), Germany (main effect for n-back, but not for digit/spatial span)2007044([@bb0190])104 healthy\
114 BDTMT number sequencing (D-KEFS), Digit Symbol coding (WAIS-III), CDT, RCFT recall, DS (WAIS-III), LNS (WAIS-III), RCFT copy, BD (WAIS-III), Similarities (WAIS-III), Verbal Fluency Test (D-KEFS), Color-Word Interference (D-KEFS), Design Fluency (D-KEFS), Tower Test (D-KEFS), CPT-No significant associations were found between CACNA1C and any cognitive domains or IQ1006737([@bb0210])96 healthy\
109 BDLNS (WAIS-III), DS (WAIS-III), TMT, and WCST-No influence of CACNA1C on cognition in HC1006737([@bb0105])1132 healthy\
552 SZJapanese versions of WMS-R, WAIS-R, and WCST-Genotype was marginally significant for logical memory for SZ patients but not HC1006737([@bb0250])401 healthy\
318 SZ\
74 BPChinese versions of WAIS-R, N-back, DPX-Healthy and SZ: Risk allele associated w impaired working memory (1-back, Bx condition of the DPX task)1006737([@bb0225])82 healthyANT-Risk homozygotes impaired in Alerting and Orienting1006737([@bb0135])63 healthy menSemantic verbal fluency-Risk carriers performed worse than non-carriers on semantic fluency tasks with abnormal activation patterns on fMRI1006737([@bb0195])530 healthy menCANTAB-No genotype effect on sensorimotor gating or CANTAB1006737([@bb0075])110 healthy3 consecutive memory test (encoding, recall, and recognition),VIQ (MWT-B), -RAVLT-Risk carriers exhibit reduction of ACC and bilateral hippocampal activation during episodic memory1006737([@bb0015])440 healthy\
282 SZ-Emotional memory, N-backRisk carriers had increased activity in hippocampus during emotion processing and in PFC during N-back1006737([@bb0215])5 childrenCELF, GFTA, NEPSY-Timothy Syndrome with Ca~V~1.2 missense mutation (G406R).\--All children showed developmental delays consistent with language, motor, and generalized cognitive impairment.1006737[^1]

In addition to genetic evidence, peripheral and postmortem markers of calcium homeostasis have been found to be abnormal in patients with SZ, suggesting that calcium channel dysregulation may be a central feature of the disorder. Calcium channel blockers, and in particular dihydropyridines (DHPs) may serve to target this dysregulation. L-type channels are highly sensitive to DHPs, which, as a class, act to block the influx of Ca2+. DHPs have been widely used as anti-hypertensives, with more recent attention given to their potential to protect from neuronal damage associated with several pathological conditions ([@bb0115]). Specifically, DHPs have been shown to block hippocampal (CA1) damage and to reduce memory impairment in animal models of hypoxia ([@bb0010]), diabetes ([@bb0240]), cerebral ischemia ([@bb0120]), and Parkinson\'s disease ([@bb0035]). Epidemiological data indicate that DHPs might prevent ([@bb0085]) or slow the progression of Alzheimer\'s disease (AD) in the general population ([@bb0090]; [@bb0235]). Results from clinical trials however have been inconsistent ([@bb0150]); some agents do not cross the blood brain barrier ([@bb0005]) and some DHPs have shown benefits only for specific genotypes ([@bb0130]). In a high-throughput screening of candidate compounds for the treatment of dementia, which included several DHPs currently in clinical use (verapamil, diltiazem, nimodipine and isradipine), only isradipine provided a significant protective benefit and minimal toxicity at multiple levels of complexity (biochemical, cellular and whole organism), making it the most promising candidate in considering efforts to target brain-based phenotypes ([@bb0050]).

Isradipine is a second-generation calcium channel blocker of the 1.4-dihydropyridine (DHP) class, which binds to both Cav1.2 and Cav1.3 channels. The Cav1.2 channel, which is specifically coded for by the CACNA1C gene, plays a critical role in hippocampal functioning and influences long term potentiation and spatial memory formation ([@bb0160]). Cav1.3 is encoded by CACNA1D and is primarily localized to the striatum ([@bb0230]). Isradipine blocks Cav1.3 channel subtypes in dopamine (DA) cells in the substantia nigra ([@bb0040]) which is believed to be at least one of the its mechanisms of action resulting in neuroprotection in animal models of Parkinson\'s disease (PD) ([@bb0040]; [@bb0045]; [@bb0185]). Isradipine has received some attention as a candidate for Alzheimer\'s Disease (AD) trials, due to data from animal models indicating its tolerability and superior blood-brain barrier penetrance, alongside its ability to attenuate beta amyloid toxicity, lower tau burden, and improve autophagy function in transgenic mouse models for AD ([@bb0005]). Isradipine has also been shown to protect against stroke ([@bb0145]) and ischemia ([@bb0025]) in rat models of hypertension. Data from a pilot trial of isradipine in PD patients indicates safety and tolerability, with an optimal daily dose of 10 mg/day ([@bb0200]).

We completed a four-week, open-label, pilot study of isradipine in a small sample (n = 10 completers) of symptomatically-stable patients with SZ. The primary goal of this pilot study was to assess the safety and feasibility of using isradipine in SZ. As a secondary aim, though underpowered to test in any definitive way, we investigated whether isradipine shows a positive signal for efficacy on the cognitive deficits in SZ.

2. Materials and methods {#s0010}
========================

This study was reviewed and approved by the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai. All patients signed an informed consent document before any study procedures were conducted.

This was an open-label study with a *flexible dosing schedule*, targeting an optimal dose of 10 mg/day ([NCT01658150](NCT01658150){#ir0005}). Patients were screened and if deemed eligible, started on 5 mg/day at baseline and if tolerated, the dose was raised to 5 mg/BID with a total of 10 mg/day. The visit schedule included weekly in-person visits to track side effects and symptom ratings. Neurocognition and functional capacity were assessed by highly trained study staff at baseline and again at week 4 or end of study.

2.1. Patients {#s0015}
-------------

Patients were recruited through local advertisements in the New York City metropolitan area from January 2013 until August 2018. Inclusion criteria included age between 18 and 55; a diagnosis of schizophrenia or schizoaffective disorder as per the Structured Clinical Interview for the DSM-IV (SCID-IV); and symptom ratings indicating a residual phase of illness (Brief Psychiatric Rating Scale BPRS item scores of ≤4 on each of the following: hallucinatory behavior, unusual thought content, and conceptual disorganization, Hamilton Rating Scale for Depression HDRS total score \< 12, and Clinician Administered Ratings Scale for Mania CARS-M total score \< 5). Exclusion criteria were 1. History of CNS trauma, neurological disorder, attention deficit hyperactivity disorder (ADHD), mental retardation, learning disability, or other known non-schizophrenic cause of cognitive impairment; 2. DSM-IV diagnosis of substance abuse/dependence within 3 months or positive urine toxicology at screening that is not consistent with what participant reported; 3. pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (including oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy); 4. women who are breastfeeding; 5. active, unstable medical problem that may interfere with cognition; 6. current treatment for hypertension; 7. uncontrolled hypertension; 8. history of heart disease; 9. any drug known to interact with isradipine; 10. history of gastrointestinal strictures; 11. abnormal lab or electrocardiogram (ECG) at screen; and 12. significant suicidal ideation at baseline (HDRS item 3 \> 2). Concomitant medications: Practical and ethical considerations prevent an exclusive focus on medication-free patients; however, we limited participation to individuals taking at least one and no \>2 concomitant antipsychotic medications and we excluded subjects who have received ECT within 12 months.

2.2. Measures {#s0020}
-------------

Safety was assessed weekly through clinician-administered and self-report measures, in addition to laboratory measures (blood pressure; heart rate; weight). An ECG was conducted at screening and at week 4. Symptom severity was rated at each visit using the Scale for the Assessment of Negative Symptoms (SANS), BPRS, and the HDRS. Cognition was assessed at baseline and at week 4 using the MATRICS Consensus Cognitive Battery (MCCB), which taps into seven domains of cognitive functioning including processing speed, attention/vigilance, working memory, verbal memory, visual memory, reasoning/problem solving, and social cognition ([@bb0165]). Alternate forms were utilized at the week 4 visit to reduce practice effects. Everyday functioning was assessed using the UCSD Performance Skills Assessment (UPSA) and Quality of Life Scale at baseline and week 4. Blood samples were collected at baseline for DNA extraction.

2.3. Statistical analyses {#s0025}
-------------------------

The results reported here are largely descriptive for safety and feasibility outcomes. To assess for efficacy on cognitive and functional outcome measures, we conducted paired-sample *t*-tests and calculated effect size changes using Cohen\'s d.

3. Results {#s0030}
==========

This proof-of-concept trial focused on feasibility and safety as primary outcomes. Efficacy on cognition was secondary and is considered very preliminary.

3.1. Demographics {#s0035}
-----------------

The sample consisted of 10 adults with a mean age of 38 ± 13.4 years, 7/10 were male, 7/10 were diagnosed with schizophrenia, and 3/10 were diagnosed with schizoaffective disorder. Race, based upon self-report, was distributed as follows: 6 Black, 2 Asian, 1 White, and 1 Mixed-race.

3.2. Feasibility {#s0040}
----------------

Recruitment was difficult, but this was not necessarily unexpected as inclusion/exclusion criteria for clinical trials are often limiting. In the case of this trial, we specifically had difficulty identifying eligible patients due to the exclusion of patients who were taking any cardiac/hypertensive medications. The second most common reason for exclusion was the high percentage of patients not currently taking a stable dose of psychotropic medications. Most of the patients that we screened via their enrollment in a larger non-intervention-based study (of \>100 patients who met diagnostic criteria) were ineligible due to these specific criteria. A total of 17 patients were consented to the study, with 6 screen fails. Screen fails were due to medication rule out, abnormal ECG, abnormal labs, positive urine toxicology, unwillingness to swallow pills, and scheduling complications ([Supplemental Fig. 1](#ec0005){ref-type="supplementary-material"}).

3.3. Safety {#s0045}
-----------

There were *no serious adverse events* reported in the conduct of this trial. There was one patient who dropped out of the study after taking study drug for 3 days. This was a 33-year-old Hispanic female patient with schizophrenia who reported headache, flushing, and lightheadedness after 3 doses of 2.5 mg/day (she was taking half of the prescribed does of 5.0 mg/day). She discontinued medication and was withdrawn from the study. All of her labs/vitals/ECG were within normal limits and all reported AEs resolved by the time she was seen at a follow-up visit one week later.

Symptom severity measures were of interest in this trial primarily for safety assessment -- to ensure that the study medication did not exacerbate psychosis, negative symptoms, or depression. Mean change for positive symptoms (BPRS) was −1.0 ± 2.5; negative symptoms (SANS) was −1.6 ± 3.3; and depressive symptoms (HDRS) was −0.6 ± 1.8. As all patients began the trial during a residual (non-acute) phase, no changes in symptom severity were of clinical concern for any patient. There were no cases of increased suicidality.

Blood pressure was closely monitored during the trial. At baseline, half of the patients (5/10) met strict criteria for hypertension (4 met Stage 1 criteria of \>130--139 diastolic or \>80--89 and 1 met Stage 2 criteria). At week 4, only 2 patients continued to be hypertensive (3 cases improved) and no new incidences were noted. The mean change in weight over the 4-week study was −0.16 (±4.1) pounds; however, there was a significant range in weight change (one patient lost 8 lbs., and another gained 5.6 lbs.).

Other common adverse events were assessed by direct query by the study physician at each visit. Details are shown in [Table 2](#t0010){ref-type="table"}. The only newly emergent side effects (change since baseline report) that were reported were dizziness (1 new incidence at week 4); difficulty sleeping (2 new incidences at week 4); and decreased energy (3 new incidences at week 4, 2 of which reported difficulty sleeping as well). As this was an open-label study, we are unable to compare the frequency of these new reports with a placebo group.Table 2Adverse events: Baseline vs. week 4 (end of study).Table 2Queried adverse events (AE)Baseline (\# reporting/10)Week 4 (\# reporting/10)NoteDiarrhea00--Constipation00--Dry Mouth00--Nausea10Resolved since baselinePalpitations00--Dizziness01New since baselineChest Pain00--Rash00--Perspiration00--Itching00--Dry skin10Resolved since baselineHeadache00--Tremors00--Poor coordination10Resolved since baselineBlurred vision10Resolved since baselineTinnitus21No change from baselineDifficulty urinating00--Painful urination00--Frequent urination21No change from baselineMenstrual irregular33No change from baselineDifficulty sleeping13Two new since baselineHypersomnia10Resolved since baselineLoss of libido10Resolved since baselineAnxiety22No change from baselinePoor concentration21New since baselineMalaise00--Restlessness11No change from baselineFatigue21No change from baselineDecreased energy03Three new since baseline

3.4. Cognitive and functional outcomes {#s0050}
--------------------------------------

This was an open-label pilot study which is inherently underpowered to truly test for clinical efficacy; however, the goal was to assay systematic signals (both positive and negative effects) on cognition and functional capacity.

Preliminary evaluation of the data indicates *no clear benefit on any measured aspect of cognition*. When comparing baseline performance on the MCCB composite with performance at week 4, we see non-significant improvement as a group (t = 0.77, df = 9, p = 0.46). Similar non-significant changes were noted across all MCCB domains ([Table 3](#t0015){ref-type="table"}). There was some variability/heterogeneity in cognitive response which is depicted at the individual patient level in [Fig. 1](#f0005){ref-type="fig"}; however, given the small sample, we are unable to determine any clear predictors of outcome.Table 3Changes in neurocognitive domains: Baseline vs. week 4 (end of study).Table 3DomainBaseline (n = 10)Week 4 (n = 10)tpMeanSDMeanSDSpeed of processing44.99.3644.710.280.080.94Attention/vigilance39.210.8039.511.29−0.080.94Working memory40.113.4640.513.87−0.160.88Verbal learning44.49.6139.34.111.690.13Visual learning48.914.0650.510.97−0.510.62Reasoning and problem solving48.213.8844.010.241.830.10Social cognition40.49.4741.011.84−0.230.82Overall composite39.713.3338.212.560.770.46Fig. 1Variability in UPSA Communication Score, depicted at the individual patient level.Fig. 1

Of note, our functional capacity measure, the UPSA communication score did improve significantly overall (baseline mean = 6.8 ± 1.3 to week 4 mean = 7.9 ± 1.1; t = 2.91, p = 0.017). This is a large effect size (Cohen\'s d = 0.91) with a more consistent pattern of improvement across subjects ([Fig. 2](#f0010){ref-type="fig"}). A recent study estimated practice effects in SZ patients administered the UPSA to be considerably smaller (Cohen\'s d = 0.35) than the change that we are reporting here ([@bb0125]). Nonetheless, given the lack of corroborating improvement on other measures of cognition and the preliminary nature of this study, it is unknown whether these gains represent clinically-meaningful change.Fig. 2Variability in MCCB composite t-score (mean = 50 SD = 10, with higher scores indicating better performance), depicted at the individual patient level.Fig. 2

4. Discussion {#s0055}
=============

This open-label pilot study provides preliminary evidence that isradipine is relatively safe when used adjunctively in patients with schizophrenia (SZ), as no serious adverse events were noted. Common side effects were minimal. By design, this study cannot determine whether the agent might be useful in treating positive or negative symptoms of the illness, as patients were very stable at the time of entry; however, there were no cases of clinical exacerbation after 4-weeks of treatment with isradipine. Mild hypertension that was present in 5 patients at baseline was normalized by week 4 in 3 of these cases.

The primary domain of interest for efficacy was cognition -- and the study was quite convincingly negative on this outcome. These data, although very preliminary, may suggest that blocking the influx of calcium, at least with isradipine, is unlikely to produce a pronounced cognitive benefit in SZ. We did find a positive change on the UPSA, indicating some improvement in functional capacity; however, this result should be interpreted with caution given the preliminary and open-label nature of this trial.

The physiological effects of isradipine are fairly well understood, with broad effects on both long-term potentiation and dopaminergic tone in subcortical areas. These effects are among the reasons that we hypothesized that isradipine might influence cognitive functioning; however, given the lack of improvement on cognitive measures in our study, it is more difficult to speculate how isradipine\'s physiological effects would influence functional capacity. Thus, the most parsimonious explanation is that these effects may be a consequence of isradipine\'s effects on hypertension. There are several lines of evidence that would support this explanation, including a recent study ([@bb0070]) which showed that elevated day-to-day variability in blood pressure was associated with greater cognitive and functional decline in patients with Alzheimer\'s disease. While SZ is not always considered to be a degenerative condition (aside from early definitions), it has a very high rate of stable cognitive impairment. Perhaps not uncoincidentally, schizophrenia also has high medical comorbidity and hypertension is common ([@bb0110]). In our study, our patients were symptomatically stable, but half of the patients met strict criteria for hypertension at baseline. Most of these patients showed significant stabilization of blood pressure by week 4, which could be a potential explanation for functional improvement in the absence of changes in symptom severity or cognitive impairment. Indeed, prior work has suggested that both psychiatric symptoms and physical functioning are major determinants of subjective disability in both patients with schizophrenia and bipolar disorder ([@bb0220]) and a recent meta-analysis demonstrates a consistent relationship between hypertension and cognitive and functional impairment in schizophrenia ([@bb0020]).

Prior studies of Ca2+ channel blockers in affective and substance disorders ([@bb0030]) are mixed and depend upon outcome measure (depression, mania, cycling, relapse) and the pharmacodynamics of the specific agent or class of agent utilized \[e.g. verapamil (a phenylalkylamine), isradipine, nimodipine (DHPs)\]. A pilot study of isradipine in depressed patients with bipolar disorder provides early evidence of a potential anti-depressant effect of this agent, but sample size was small and there were no measures of cognition or functioning reported ([@bb0175]). Of relevance to our work, [@bb0140] conducted a double-blind, placebo-controlled trial of nimodipine in 26 alcohol-dependent men as a pre-treatment to ketamine, an NMDA receptor antagonist which can produce SZ-like syndromes including psychosis, negative symptoms, and cognitive impairment in healthy humans. Nimodipine pre-treatment significantly attenuated the effects of ketamine with regard to psychosis, negative symptoms, dysphoria, verbal fluency impairment and learning deficits. In fact, nimodipine not only reduced the capacity of ketamine to induce memory deficits but actually improved memory performance in this cohort. These results alongside convergent evidence that calcium channel dysfunction represents a core pathogenic feature in SZ, support continued evaluation of DHPs, in general, in neuropsychiatric disorders.

Our study had several limitations including its open-label design and the small sample size. Although we only had a total of 10 completers, there was no compelling evidence of any positive cognitive effects in the first ten participants and the risk of exposing additional subjects to an experimental drug was deemed to outweigh the benefits of continuing to enroll for the sake of statistical power. In addition, the decision to focus on stable patients in the residual phase was done to reduce the chances of pseudospecificity and to isolate potential effects on neurocognition. This design did not allow us to test the effects of isradipine on clinical symptoms of SZ.

Despite the negative outcome, this was a proof of concept study that provides important early data on safety and feasibility of using isradipine in patients with SZ. There remains a possibility that the heterogeneity in cognitive response that was noted may be related to genetic variation in the *CACNA1C* gene. Given the small sample, we do not anticipate any measurable main effects of genotype, but a genotype-specific response remains a plausible, testable hypothesis -- which could inform whether future studies stratified by genotype may be warranted.

The following are the supplementary data related to this article.Supplemental Fig. 1Most of the patients that were screened via their enrollment in a larger non-intervention-based study (of \>100 patients who met diagnostic criteria) were ineligible. A total of 17 patients were consented to the study, with 6 screen fails. Screen fails were due to medication rule out, abnormal ECG, abnormal labs, positive urine toxicology, unwillingness to swallow pills, and scheduling complications.Supplemental Fig. 1
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[^1]: Key: HC = healthy controls, BD = bipolar disorder, SZ = schizophrenia, SZA = schizoaffective disorder, SWM = Spatial Working Memory, CANTAB = Cambridge Neuropsychological Test Automated Battery, MATRICS = Measurement and Treatment Research to Improve Cognition in Schizophrenia, DS = digit span, WAIS-III = Wechsler Adult Intelligence Scale version III, SS = spatial span, TMT = Trails Making Task, D-KEFS = Delis-Kaplan Executive Function System, CDT = Claeson-Dahl Test, RCFT = Rey Complex Figure Test, LNS = letter-number sequencing, BD = Block Design, CPT = Continuous Performance Test, WCST = Wisconsin Card Sorting Task, WMS-R = Wechsler Memory Scale-Revised, WAIS-R = Wechsler Adult Intelligence Scale-Revised, DPX = Dot Pattern expectancy, ANT = Attention Network Test, VIQ = Verbal Intelligence Quotient, MWT-B = Mehrfachwahl-Wortschatz-Intelligenztest, version B, RAVLT = Rey Auditory Learning Task, CELF = Clinical Evaluation of Language Fundamentals, GFTA = Goldman-Fristoe Test of Articulation, NEPSY = A Developmental Neuropsychological Assessment.
